| 1 | Multicenter evaluation of the Panbio TM COVID-19 Rapid |
|----|---|
| 2 | Antigen-Detection Test for the diagnosis of SARS-CoV-2 infection |
| 3 | Paloma Merino-Amador ¹ , Jesús Guinea ² , Irene Muñoz-Gallego ^{3,} Patricia González- |
| 4 | Donapetry ⁴ , Juan-Carlos Galán ^{5,6} , Nerea Antona ⁷ , Gustavo Cilla ⁸ , Silvia Hernáez- |
| 5 | Crespo ⁹ , José-Luis Díaz-de Tuesta ¹⁰ , Ana Gual-de Torrella ¹¹ , Fernando González- |
| 6 | Romo ¹ , Pilar Escribano ² , Miguel Ángel Sánchez-Castellano ⁴ , Mercedes Sota-Busselo ¹² , |
| 7 | Alberto Delgado-Iribarren ¹ , Julio García ⁴ , Rafael Cantón ^{5,13} , Patricia Muñoz ² , M |
| 8 | Dolores Folgueira ^{3,14,15} , Manuel Cuenca-Estrella ^{16*} , Jesús Oteo-Iglesias ^{13,17*#} , and |
| 9 | Spanish Panbio [™] COVID-19 validation group‡ |
| 10 | |
| 11 | ¹ Microbiology Department, Hospital Universitario Clínico San Carlos, Madrid, Spain |
| 12 | ² Microbiology Department, Hospital Universitario Gregorio Marañón, Madrid, Spain. |
| 13 | ³ Clinical Microbiology Department, Hospital Universitario Doce de Octubre, Madrid, |
| 14 | Spain. |
| 15 | ⁴ Microbiology Department, Hospital Universitario La Paz, Madrid, Spain. |
| 16 | ⁵ Microbiology Department, Hospital Universitario Ramón y Cajal e Instituto Ramón y |
| 17 | Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain. |
| 18 | ⁶ CIBER de Investigación en Salud Pública (CIBERESP). Madrid. Spain |
| 19 | ⁷ Osakidetza Basque Health Service, Hospital Universitario Cruces, Microbiology |
| 20 | Department, Barakaldo, Spain. |
| 21 | ⁸ Health Research Institute, Biodonostia, San Sebastián, Spain; Osakidetza Basque |
| 22 | Health Service, Hospital Universitario Donostia, Microbiology Department, San |
| 23 | Sebastián, Spain. |
| 24 | ⁹ Osakidetza Basque Health Service, Hospital Universitario Araba, Microbiology |
| 25 | NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. |

| 26 ¹ | ⁰ Osakidetza | Basque | Health S | Service, | Hospital | Universitario | Basurto, | Microbiology | y |
|-----------------|-------------------------|--------|----------|----------|----------|---------------|----------|--------------|---|
|-----------------|-------------------------|--------|----------|----------|----------|---------------|----------|--------------|---|

27 Department, Bilbao, Spain.

| 28 | ¹¹ Osakidetza Baso | ue Health Service | , Hospital Universitario | Galdakao-Usansolo, |
|----|-------------------------------|----------------------|---------------------------|--------------------|
| | Obuindetha Dube | 100 1100101 001 1100 | , Hospital elliversitalle | ouraunao obumbore |

- 29 Microbiology Department, Galdakao, Spain.
- ¹²Osakidetza Basque Health Service, Hospital Universitario Donostia, Clinical
- 31 Management Unit of Gipuzkoa Laboratories, San Sebastián, Spain⁻
- ¹³Spanish Network for Research in Infectious Diseases (REIPI)
- ¹⁴Instituto de Investigación Hospital 12 de Octubre, imas12, Madrid, Spain.
- ¹⁵Department of Medicine, Universidad Complutense School of Medicine, Madrid,

35 Spain.

- ¹⁶ Instituto de Salud Carlos III, Majadahonda, Madrid, Spain.
- ¹⁷National Centre for Microbiology, Instituto de Salud Carlos III, Majadahonda,
- 38 Madrid, Spain.
- 39
- 40 *Manuel Cuenca-Estrella and Jesús Oteo-Iglesias contributed equally to this work.
- 41 ‡ Members of the Group are listed in Acknowledgements
- 42
- 43 **Running title:** Evaluation of the PanbioTM COVID-19 Ag Rapid Test
- 44 Keywords: COVID-19; rapid antigen-detection test; SARS-CoV-2
- 45

46 **# Corresponding autor**:

- 47 Jesús Oteo-Iglesias, National Centre for Microbiology, Instituto de Salud Carlos III,
- 48 Carretera Pozuelo a Majadahonda, 28220 Majadahonda, Madrid, Spain.
- 49 Phone: ++34 918 22 3650. Fax: ++34 915097966.
- 50 Email: jesus.oteo@isciii-es

51 Abstract

The standard RT-PCR assay for COVID-19 is laborious and time-consuming, limiting 52 the availability of testing. Rapid antigen-detection tests are faster and less expensive; 53 however, the reliability of these tests must be validated before they can be used widely. 54 The objective of this study was to determine the reliability of the PanbioTM COVID-19 55 Ag Rapid Test Device (PanbioRT) (Abbott) for SARS-CoV-2 in nasopharyngeal swab 56 57 specimens. This was a prospective multicenter study in ten Spanish university hospitals of patients from hospital units with clinical symptoms or epidemiological criteria for 58 COVID-19. Patients whose onset of symptoms or exposure was more than 7 days earlier 59 were excluded. Two nasopharyngeal exudate samples were taken to perform the 60 PanbioRT and a diagnostic RT-PCR test. Among the 958 patients studied, 359 (37.5%) 61 were positive by RT-PCR and 325 (33.9%) were also positive by the PanbioRT. 62 Agreement was 95.7% (kappa score: 0.90). All 34 false-negative PanbioRT results were 63 in symptomatic patients, with 23.5% of them at 6-7 days since the onset of symptoms 64 and 58.8% presenting C_T >30 values for RT-PCR, indicating a low viral load. Overall 65 sensitivity and specificity for the PanbioRT were 90.5% and 98.8%, respectively. The 66 PanbioRT provides good clinical performance as a point-of-care test, with even more 67 68 reliable results for patients with a shorter clinical course of the disease or a higher viral 69 load. While this study has had a direct impact on the national diagnostic strategy for 70 COVID-19 in Spain, the results must be interpreted based on the local epidemiological 71 context.

72

73

75 Introduction

The novel coronavirus SARS-CoV-2, which causes severe acute respiratory syndrome, 76 emerged in Wuhan (China) in December 2019. The virus has spread rapidly, causing a 77 global pandemic that was defined by The World Health Organization (WHO) as 78 Coronavirus disease-19 (COVID-19) (1). Reliable and early diagnosis of the responsible 79 agent, not only in symptomatic patients but also in close contacts of confirmed cases, is 80 81 critical to controlling the spread of the disease (2,3). Clinical diagnosis of COVID-19 has relied on nucleic acid amplification tests, such as real-time reverse transcription 82 polymerase chain reaction (RT-PCR) assays to detect SARS-CoV-2 (3,4). RT-PCR, the 83 current standard for COVID-19 diagnosis, is also the standard test in clinical 84 microbiology laboratories for the diagnosis of many infections because the test is 85 sensitive and pathogen-specific. However, the method is laborious, requiring 86 inactivation of the virus and RNA extraction before the RT-PCR assay. The test (under 87 optimal conditions) takes approximately 4-5 h, and the response time is typically 12 to 88 24 h. This test also requires a continuous supply of PCR kits as well as swabs and 89 transport media for samples, inactivation solutions, extraction reagents, and disposable 90 plasticware. The WHO recommended at least 200 PCR tests per 100,000 population to 91 92 ensure adequate control of the pandemic; however, in Spain more than 1,500 PCR tests per 100,000 population were performed in September and October 2020 (5). This high 93 94 level of testing will be difficult to maintain in winter because of testing for other 95 respiratory infections, such as influenza. Therefore, we risk saturating the PCR-testing capacity of microbiology laboratories, but also of sampling capacities in primary care 96 97 centers.

98 There are ongoing efforts to develop fast, reliable, and inexpensive diagnostic tests
99 specific for detection of SARS-CoV-2 antigens. Rapid antigen-detection tests (RADT)

100 for both laboratory and near-patient use detect SARS-CoV-2 proteins produced by replicating viruses in respiratory secretions (6). The PanbioTM COVID-19 Ag Rapid 101 Test Device (PanbioRT) (Abbott Diagnostic GmbH, Jena, German) is a rapid in vitro 102 test for the qualitative detection of the viral nucleocapsid protein in nasopharyngeal 103 104 swab specimens from individuals who meet clinical and/or epidemiological criteria of 105 COVID-19 infection. This is a novel, lateral-flow-format test that uses immunochromatography with colloidal gold in a point-of-care format, with results in 106 107 15-20 min. The objective of this study is to determine the reliability of the PanbioRT with CE marking. 108

109

110 Materials and Methods

This was a prospective multicenter diagnostic evaluation study across ten independent 111 112 university hospitals in two Spanish autonomous communities (Madrid and Basque Country) using consecutive enrollment. The hospitals participating in the study from 113 Madrid were Hospital Clínico Universitario San Carlos, Hospital Universitario Ramón y 114 Cajal, Hospital Universitario La Paz, Hospital Universitario Doce de Octubre, and 115 Hospital Universitario Gregorio Marañón. Hospitals from Basque Country were 116 117 Hospital Universitario Araba, Hospital Universitario Cruces, Hospital Universitario 118 Basurto, Hospital Universitario Donostia, and Hospital Universitario Galdakao-119 Usansolo. Patients with clinical symptoms or epidemiological criteria (asymptomatic 120 close contacts) for COVID-19 from hospital emergency rooms or other hospital units 121 who were to receive a diagnostic RT-PCR test were included in the study. All participants were reported as part of the study and verbal informed consent was 122 123 obtained prior to their inclusion. The result of the PanbioRT did not influence the 124 clinical management of the patients, which was decided based on the RT-PCR result.

Patient data were coded and no samples were stored after the PanbioRT was performed.
Patients whose onset of symptoms or exposure was more than 7 days earlier were
excluded.

Two nasopharyngeal exudate samples were taken per patient: one was used immediately by trained personnel to perform the PanbioRT according to the manufacturer's instructions, and the second was used for a molecular diagnostic (RT-PCR) by each hospital according to its standard procedures for COVID-19 diagnosis.

132 The symptoms, number of days since the onset of symptoms or exposure, threshold

133 cycle (C_T) values for PCR, and demographic data were collected for all participants.

Specificity and sensitivity with 95% confidence intervals (CI) were calculated using the RT-PCR results as the standard. Sensitivity was calculated for all patients and for specific groups of patients according to the time of onset of symptoms or exposure, RT-PCR C_T values, symptoms, and age. The level of agreement between the tests was evaluated using Cohen's kappa score (7).

139

140 **Results**

Between September and October 2020, 958 individuals who had at least one symptom compatible with COVID-19 (n=830) or had been in close contact with a diagnosed COVID-19 patient (n=128) were included in this study. There were between 8 and 245 individuals from each participating hospital with a mean age of 42.4 years (range, 1-100); 61.3% were women (Table 1) and 58 cases were in pediatric patients (\leq 14 years old).

Among these 958 patients, 359 (37.5%) were positive by RT-PCR and 325 (33.9%)
were also positive by the PanbioRT (Table 2). A total of 599 (62.5%) were negative by
PCR and 592 (61.8%) were also negative by the PanbioRT (Table 2). The agreement

between both methods was 95.7% (kappa score: 0.90; CI 95%: 0.88–0.93). In 41 patients the results differed between the two tests and most of the differences were in individuals who tested positive with the RT-PCR test but negative with the PanbioRT (n=34; 3.5%) (Table 2, Table 3). All 34 of these cases were in symptomatic patients, with 8 (23.5%) of them at 6–7 days since the onset symptoms, and 20 (58.8%) had C_T>30 values for RT-PCR.

156 Based on these data, the overall sensitivity and specificity of the PanbioRT were 90.5%

157 (CI 95%: 87.5–93.6) and 98.8% (CI 95%: 98–99.7), respectively (Table 3). Sensitivity

use slightly higher in patients with ≤ 5 days of the clinical course of the disease (91.8%;

159 CI 95%: 88.8–94.8) or in those who had a $C_T < 30$ for the RT-PCR test (94.5%; CI 95%:

160 91.7–97.3) (Table 4).

Among the 128 asymptomatic participants who had close contact with a COVID-19 patient, there was full concordance in the 31 (24.2%) who were positive by RT-PCR and in the 97 that were negative. Six (10.3%) of the 58 pediatric patients included in the study were positive by RT-PCR and also by the PanbioRT.

The negative predictive value (NPV) and positive predictive value (PPV) in the study cohort, with a high prevalence (37.5%), were 94.6% and 97.8%, respectively (Table 4). PPV and NPV were also calculated for lower prevalence of 5% and 10%; the results obtained were 79.8% and 89.3%, respectively, for PPV; and 99.5 and 98.9%, respectively, for NPV.

170

171 **Discussion**

As the COVID-19 pandemic continues unabated, the gap between the number of tests that are needed and the testing capacity of laboratories or in primary care settings increases (3). RADT tests are simple to perform and interpret without the need for

equipment at the point-of-care, they are inexpensive, and they provide quick results. 175 Early rapid antigen-detection test for COVID-19 diagnosis had poor reliability that 176 177 precluded their general use (8-11); however, the new generation of RADT appear to have substantially improved reliability (12-15). Although these rapid tests show promise 178 for use as part of a larger strategy for COVID-19 diagnosis and control (6), there are 179 180 insufficient validation studies to support their use in varied patient environments. In this study the PanbioRT gave very good clinical performance values, with 90.5% sensitivity 181 182 and 98.8% specificity; moreover, sensitivity was even improved in patients with five or fewer days of clinical progression of the disease. The strengths of this study include the 183 large study size, the high percentage of positive cases, the inclusion of multiple centers, 184 the prospective nature of the study, and the inclusion of point-of-care patients. This 185 186 study has had an immediate clinical impact, having been used to modify the Spanish 187 Strategy for Early Detection, Surveillance, and Control, of COVID-19 (Update September 25, 2020) (16). 188

189 In two recent pre-published Spanish studies with 412 patients (54 positive by RT-PCR) 190 (13) and 255 patients (60 positive by RT-PCR) (12), the overall sensitivities were 191 79.3% and 76.3%, respectively; however, in the second study sensitivity was 86.5% in 192 symptomatic patients with seven or fewer days since the onset of symptoms (12). WHO 193 guidelines require that SARS-CoV-2 RADT demonstrate \geq 80% sensitivity and \geq 97% specificity compared to the RT-PCR reference assay (6). Thus, our data support the 194 195 clinical use of the PanbioRT instead of the RT-PCR test in patients with symptoms of COVID-19 with a short clinical course (\leq 5–7 days) of the disease. Although the results 196 197 obtained in asymptomatic patients and children under 14 years of age were good, the 198 number of cases included for these subpopulations was small (128 and 58, respectively), making it inadvisable to conclude general results about that. In a pre-published study 199

with frozen samples (17), sensitivity was significantly higher among samples collected in the setting of case identification (92.6%) and contact tracing (94.2%) than in asymptomatic screening (79.5%). This is consistent with the advice from the WHO against using RADT for screening asymptomatic individuals in populations with low COVID-19 prevalence (6) due to the potential increase of higher incidence of false positives. In this study, we estimated that the PPV decreased to 79.8% when the prevalence was 5%.

207 The performance of an RADT may depend on the epidemiological situation of the 208 population being tested; therefore, how the test is used and how the results are interpreted will depend on local epidemiological factors (6). In populations with a high 209 prevalence and a high frequency of symptomatic patients, a positive rapid test would be 210 considered confirmatory for infection. However, a negative result would lead to further 211 212 testing for respiratory pathogens, including an RT-PCR test for COVID-19 if the symptoms were consistent with this disease. In populations with a low prevalence of 213 214 COVID-19 and more asymptomatic patients, a negative test would be accepted, but a 215 positive test, which is more likely to be false, could require a confirmatory RT-PCR 216 test.

The use of RADT as a diagnostic tool can greatly reduce the testing burden on microbiology laboratories. However, in the primary care setting, which has also reached saturation in the testing and diagnosis of COVID-19, changes would be required to allow them to perform the rapid test on-site. The ability to perform this test in patient care centers would simplify the process of testing, provide rapid results to the doctor and the patient, thus improving the decision-making process and reducing pressure on the health care providers.

In conclusion, this study showed that the PanbioRT provides very good clinical performance as a point-of-care test, with even better results for patients with a shorter clinical course of the disease or higher viral load. While this study has had a direct impact on the national diagnostic strategy for COVID-19 in Spain, the results must be interpreted based on the local epidemiological context. The ease and speed of RADT with god clinical performance could help to prevent an overload on health care services as laboratories will have to cope with an increase in respiratory infections during winter.

231

232 Acknowledgments

We thank Abbott Diagnostics for providing Panbio[™] COVID-19 AG Rapid Test
Device kit and all the professionals involved in the diagnosis of COVID-19 in the
participating hospitals.

236 Members of the Spanish PanbioTM COVID-19 validation group are:

237 Sara Medrano and Alba Pérez (H. Universitario Clínico San Carlos), Oscar Martínez-

238 Expósito (H. Universitario Cruces), Izaskun Alejo-Cancho (H. Universitario Galdakao),

239 M. Carmen Martín-Higuera and Marta Rolo (H. Universitario Doce de Octubre), Mª

240 Jesús Estévez and Tania Bravo (H. Universitario Ramón y Cajal), Diego Vicente and

241 Mila Montes (H. Universitario Galdakao-Usansolo).

243 **References.**

1. WHO, Coronavirus Disease (COVID-2019) Situation Report-51, 11 March 2020.

245 Available from: <u>https://www.who.int/docs/default-source/coronaviruse/situation-</u>

246 reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10

- 247 2. Nguyen T, Duong Bang D, Wolff A. 2020. 2019 Novel coronavirus disease (COVID-
- 248 19): Paving the road for rapid detection and point-of-care diagnostics. Micromachines
- 249 (Basel) 11: 306. https://doi.org/10.3390/mi11030306. PMID: 32183357; PMCID:
- 250 PMC7142866.

3. WHO, Laboratory Testing Strategy Recommendations for COVID-19. Interim
Guidance, 21 March 2020. Available from:
https://apps.who.int/iris/handle/10665/331509.

- 4. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T,
- 255 Brünink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van
- 256 den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M,
- 257 Goossens H, Reusken C, Koopmans MP, Drosten C. 2020. Detection of 2019 novel
- coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill 25(3): 2000045.
 https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045
- 260 5. Spanish Ministry of Health. Enfermedad por el nuevo coronavirus COVID-19.
 261 Situación actual. Available from:
- 262 <u>https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/home.</u>
 263 htm
- 6. WHO, Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid
 immunoassays. Interim guidance, 11 September 2020. Available from:
 <u>https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-</u>
 2infection-using-rapid-immunoassays.
- 7. McHugh ML. 2012. Interrater reliability: the kappa statistic. Biochem Med (Zagreb)
 269 22: 276-82.
- 8. Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L,
 Roque-Afonso AM, Le Goff J, Delaugerre C. 2020. Evaluation of a rapid diagnostic
 assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. J Clin Microbiol
- 273 58: e00977-20. <u>https://doi.org/10.1128/JCM.00977-20</u>

9. Blairon L, Wilmet A, Beukinga I, Tré-Hardy M. 2020. Implementation of rapid 274 SARS-CoV-2 antigenic testing in a laboratory without access to molecular methods: 275 hospital. J Clin 129: 276 Experiences of general Virol 104472. a https://doi.org/10.1016/j.jcv.2020.104472 277

10. Scohy A, Anantharajah A, Bodéus M, Kabamba-Mukadi B, Verroken A, RodriguezVillalobos H. 2020. Low performance of rapid antigen detection test as frontline testing
for COVID-19 diagnosis. J Clin Virol 129:104455. https://doi.org/
10.1016/j.jcv.2020.104455

11. Mak GC, Cheng PK, Lau SS, Wong KK, Lau CS, Lam ET, Chan RC, Tsang DN.
Evaluation of rapid antigen test for detection of SARS-CoV-2 virus. 2020. J Clin Virol
129:104500. https://doi.org/10.1016/j.jcv.2020.104500.

12. Linares M, Pérez-Tanoira R, Romanyk J, Pérez-García F, Gómez-Herruz P, Arroyo
T, Cuadros J. 2020. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2
infection in the first 7 days after the onset of symptoms. medRxiv preprint
2020.09.20.20198192. https://doi.org/10.1101/2020.09.20.20198192.

289 13. Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MA, Martínez

291 Navarro D. Field evaluation of a rapid antigen test (Panbio[™] COVID-19 Ag Rapid Test

M, Poujois S, Forqué L, Valdivia A, Solano de la Asunción C, Ferrer J, Colomina J,

292 Device) for the diagnosis of COVID-19 in primary healthcare centers. medRxiv preprint

293 2020.10.16.20213850. https://doi.org/10.1101/2020.10.16.20213850.

290

14. Porte L, Legarraga P, Vollrath V, Aguilera X, Munita JM, Araos R, Pizarro G, Vial
P, Iruretagoyena M, Dittrich S, Weitzel T. 2020. Evaluation of a novel antigen-based
rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples. Int J Infect
Dis 99: 328-333. https://doi.org/10.1016/j.ijid.2020.05.098.

15. Young S, Taylor SN, Cammarata CL, Varnado KG, Roger-Dalbert C, Montano A,

299 Griego-Fullbright C, Burgard C, Fernandez C, Eckert K, Andrews JC, Ren H, Allen J,

300 Ackerman R, Cooper CK. 2020. Clinical evaluation of BD Veritor SARS-CoV-2 point-

301 of-care test performance compared to PCR-based testing and versus the Sofia 2 SARS

Antigen point-of-care test. J Clin Microbiol. <u>https://doi.org/10.1128/JCM.02338-20</u>

303 16. Spanish Ministry of Health. Estrategia de detección temprana, vigilancia y control
304 de COVID-19 (Update September 25, 2020). Available from:

- https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov/docu 305 306 mentos/COVID19_Estrategia_vigilancia_y_control_e_indicadores.pdf
- 307 17. Alemany A, Baro B, Ouchi D, Ubals M, Corbacho-Monné M, Vergara-Alert J,
- Rodon J, Segalés J, Esteban C, Fernandez G, Ruiz L, Bassat Q, Clotet B, Ara J, Vall-308
- 309 Mayans M, G-Beiras C, Blanco I, Mitjà O. Analytical and clinical performance of the
- Panbio COVID-19 Antigen-Detecting Rapid Diagnostic Test. medRxiv preprint doi: 310
- https://doi.org/10.1101/2020.10.30.20223198 311
- 312
- 313
- 314

- Table 1. Study cohort included in the validation study of PanbioTM COVID-19 Ag
- Rapid Test Device.

| Total N (valid PCR results) | 958 |
|-----------------------------|-----------------|
| Positive PCR [% (n)] | 37.5% (359) |
| Age [mean (min–max)] | 42.4 (1–100) |
| Gender [% F, (n/N)] | 61.3% (587/958) |
| Symptoms present [% Yes, | 86.6% (830/958) |
| (n/N)] | |
| Days from symptom onset or | 2.8 (958) |
| from exposure [mean (N)] | |
| Days ≤5 [n/N (%)] | 854/958 (89.1%) |
| Days 6–7 [(n/N (%)] | 104/958 (10.9%) |
| PCR $C_T(\mathbf{n})$ | 295 |
| $C_T \ge 30 [n/N, (\%)]$ | 41 (13.9%) |
| $C_T < 30 [n/N, (\%)]$ | 254 (86.1%) |

- Table 2. Summary of the results of the PanbioTM COVID-19 Ag Rapid Test Device
- compared to RT-PCR.

| | Panbio ^T | Panbio TM COVID-19 Ag Rapid Test Device | | | | |
|----------|---------------------|--|-------|--|--|--|
| RT-PCR | Positive | Negative | TOTAL | | | |
| Positive | 325 | 34 | 359 | | | |
| Negative | 7 | 592 | 599 | | | |
| TOTAL | 332 | 626 | 958 | | | |

| Sex | Compatible | Days since | Panbio result | RT-PCR result | C _T RT-PCR |
|--------|------------|----------------|---------------|----------------------|-----------------------|
| | symptoms | symptoms onset | | | |
| Male | Yes | 1 | Negative | Positive | 27 |
| Female | Yes | 1 | Negative | Positive | 34 |
| Male | Yes | 5 | Negative | Positive | 25 |
| Male | Yes | 6 | Negative | Positive | 29 |
| Female | Yes | 6 | Negative | Positive | 31 |
| Male | Yes | 5 | Negative | Positive | 26 |
| Female | Yes | 1 | Negative | Positive | 32 |
| Female | Yes | 2 | Negative | Positive | 37 |
| Female | Yes | 1 | Negative | Positive | 28 |
| Male | Yes | 3 | Negative | Positive | 32 |
| Male | Yes | 1 | Negative | Positive | 32 |
| Female | Yes | 7 | Negative | Positive | 30 |

Table 3. Cases with discordant results between the RT-PCR method and the PanbioRT.

| Male | Yes | б | Negative | Positive | 31 |
|--------|-----|---|----------|----------|----|
| Female | Yes | 2 | Negative | Positive | 26 |
| Female | Yes | 2 | Negative | Positive | 36 |
| Female | Yes | 1 | Negative | Positive | 30 |
| Female | Yes | 3 | Negative | Positive | 37 |
| Female | Yes | 5 | Negative | Positive | 35 |
| Female | Yes | 3 | Negative | Positive | 29 |
| Female | Yes | 3 | Negative | Positive | 26 |
| Female | Yes | 7 | Negative | Positive | 25 |
| Female | Yes | 2 | Negative | Positive | 26 |
| Female | Yes | 4 | Negative | Positive | 31 |
| Female | Yes | 3 | Negative | Positive | 34 |
| Male | Yes | 1 | Negative | Positive | 34 |
| Female | Yes | 7 | Negative | Positive | 38 |
| Male | Yes | 3 | Negative | Positive | 34 |

| Female | Yes | 4 | Negative | Positive | 34 |
|--------|-----|---|----------|----------|----|
| Female | Yes | 7 | Negative | Positive | 38 |
| Male | Yes | 3 | Negative | Positive | 34 |
| Male | Yes | 1 | Negative | Positive | 32 |
| Female | Yes | 3 | Negative | Positive | 37 |
| Female | Yes | 5 | Negative | Positive | 28 |
| Male | Yes | 7 | Negative | Positive | 30 |
| Female | Yes | 6 | Positive | Negative | |
| Male | Yes | 7 | Positive | Negative | |
| Female | Yes | 1 | Positive | Negative | |
| Female | Yes | 1 | Positive | Negative | |
| Male | Yes | 1 | Positive | Negative | |
| Female | Yes | 3 | Positive | Negative | |
| Female | Yes | 5 | Positive | Negative | |

Table 4. Estimation of clinical performance of the PanbioTM COVID-19 Ag Rapid Test Device compared to RT-PCR.

| Relative Sensitivity (CI 95%) | 90.5% (87.5–93.6) |
|------------------------------------|------------------------|
| Sensitivity days ≤5 (CI 95%) | 91.8% (88.8–94.8) |
| Sensitivity $C_T < 30$ (CI 95%) | 94.5% (91.7–97.3) |
| Relative Specificity (CI 95%) | 98.8% (98–99.7) |
| Agreement (kappa index; CI 95%) | 95.7% (0.9; 0.88–0.93) |
| Positive predictive value (CI 95%) | 97.8% (96.3–99.4) |
| Negative predictive value (CI 95%) | 94.6% (92.8–96.3) |